Immucell Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $30.7M+15.8% YoYTTM through 30 Jun 2026
Net Income $787.4KTTM through 30 Jun 2026
Free Cash Flow $4.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 41.4% |
| EBITDA Margin | 20.5% |
| Operating Margin | 6.0% |
| Net Margin | 2.6% |
Returns
-3.8%ROE
-2.5%ROA
2.6%ROIC
Balance Sheet Health
Debt / Equity0.34x
Current Ratio4.75x
Net Debt$5.3M
Cash & Equivalents$8.9M
Quality Metrics
Altman Z-Score4.59
Piotroski F-Score7 / 9
FCF Margin13.7%
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2025: $27.6M
Diluted EPS$0.07TTMFY2025: $-0.12
Dividend
No dividend
Capital Allocation
R&D Spend$1.9M
Capex Intensity5.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| First Defense Product Line | $27.4M | View detailsFocusing entirely on First Defense capacity expansion following the strategic pivot in December 2025 to pause Re-Tain investments. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.